** Shares of Dr. Reddy's Laboratories REDY.NS down 4.5% at 1,232 rupees, top loser on benchmark Nifty 50 .NSEI
** Co misses Q3 FY25 profit misses estimates and warns of drop in key product Lenalidomide's sales in H2 of FY26
** Lenalidomide is a generic of Bristol-Myers's cancer drug Revlimid
** Nuvama says "As gRevlimid is nearing the cliff, investor attention is focused on how DRL offsets the gRevlimid impact on earnings"; adds key product approvals is critical
** Already weak Lenalidomide sales of led to 11% sequential decline in REDY's Q3 North America sales
** Jefferies notes increased competition in North America
** Session's loss trims 12 month stock price gain to 5.07%
(Reporting by Ananta Agarwal in Bengaluru)
((Ananta.Agarwal@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。